Employees: 02 (2023.0)Legal category: Société à responsabilité limitée (sans autre indication)Size: PMECreation date: 2015-04-07 (11 years)Status: ActiveBusiness sector: Commerce de détail de produits pharmaceutiques en magasin spécialiséLocation: SAINT-YZAN-DE-SOUDIAC (33920), Gironde
Les données financières de cette entreprise sont partiellement disponibles (liasse simplifiée ou données confidentielles). Certaines sections ne sont pas affichées.
EURL PHARMACIE SAINT YZAN : revenue, balance sheet and financial ratios
EURL PHARMACIE SAINT YZAN is a French company
founded 11 years ago,
specialized in the sector Commerce de détail de produits pharmaceutiques en magasin spécialisé.
Based in SAINT-YZAN-DE-SOUDIAC (33920),
this company of category PME
shows in 2024 a net income positive of 111 k€.
Find below the complete financial statements, solvency ratios, working capital requirements and sector comparison.
Financial history - EURL PHARMACIE SAINT YZAN (SIREN 810971184)
Indicator
2024
2023
2022
2021
2020
2019
2017
2016
Revenue
N/C
N/C
N/C
N/C
N/C
N/C
N/C
N/C
Net income
111 287 €
108 878 €
217 296 €
220 707 €
180 255 €
180 575 €
229 068 €
210 340 €
EBITDA
N/C
N/C
N/C
N/C
N/C
N/C
N/C
N/C
Net margin
N/C
N/C
N/C
N/C
N/C
N/C
N/C
N/C
Revenue and income statement
In 2024, EURL PHARMACIE SAINT YZAN generates positive net income of 111 k€. Net income represents the final profit after all expenses (operating, financial, exceptional) and corporate tax. Change over 2016-2024: 210 k€ -> 111 k€.
Net income (2024)
?
Net income
Definition
Profit or loss after all expenses, including taxes and exceptional items.
Formula
Current income + Exceptional income - Income tax
111 287 €
Loading income statement...
Income statement
Item
Amount
% Revenue
Change
The detailed income statement is not available for this company (simplified accounts or confidential data).
Chart evolution
Show :
Visualization created via numbers.finance Sources : INPI & BCE - Adjustments : Ministry of Economy
Assets
Loading data...
Item
Gross
Deprec.
Net
%
Change
Assets balance sheet data not available for this company
Liabilities
Loading data...
Item
Year
%
Change
Liabilities balance sheet data not available for this company
Solvency and debt ratios
The debt ratio (= Financial debt / Equity x 100) stands at 40%. Debt remains under control: the company retains capacity to raise new debt if needed. Financial autonomy (= Equity / Total assets x 100) reaches 64%. This high autonomy means the company finances most of its assets through equity, a sign of strength.
Debt ratio (2024)
?
Debt ratio
Definition
Measures the proportion of debt to equity.
Formula
(Financial debt / Equity) x 100
Interpretation
< 50% : Low 50-100% : Moderate > 100% : High
39.756%
Financial autonomy (2024)
?
Financial autonomy
Definition
Share of equity in the company's total financing.
Formula
(Equity / Total assets) x 100
Interpretation
> 30% : Good autonomy 20-30% : Average < 20% : Low
64.27%
Asset age ratio (2024)
?
Asset age ratio
Definition
Measures the degree of wear of tangible assets.
Formula
Accumulated depreciation / Gross fixed assets x 100
Solvency indicators evolution EURL PHARMACIE SAINT YZAN
Visualization created via numbers.finance Sources : INPI & BCE - Adjustments : Ministry of Economy
Indicator
2016
2017
2019
2020
2021
2022
2023
2024
Debt ratio
626.483
554.468
717.115
390.522
203.178
85.836
59.652
39.756
Financial autonomy
11.635
14.201
10.972
19.448
30.742
47.882
57.231
64.27
Repayment capacity
None
None
None
None
None
None
None
None
Cash flow / Revenue
None%
None%
None%
None%
None%
None%
None%
None%
Sector positioning
Debt ratio
39.762024
2022
2023
2024
Q1: 16.46
Med: 58.48
Q3: 154.77
Good-14 pts over 3 years
In 2024, the debt ratio of EURL PHARMACIE SAINT YZAN (39.76) ranks below the median of the sector. This ratio measures the weight of debt relative to equity. This controlled position reflects prudent management.
Financial autonomy
64.27%2024
2022
2023
2024
Q1: 28.91%
Med: 49.95%
Q3: 69.47%
Good+17 pts over 3 years
In 2024, the financial autonomy of EURL PHARMACIE SAINT YZAN (64.3%) ranks above the median of the sector. This ratio represents the share of equity in total financing. This comfortable position offers an appreciable safety margin.
Liquidity ratios
The liquidity ratio (= Current assets / Current liabilities) stands at 158.00. Concretely, the company has €2 of liquid assets for every €1 of short-term debt: no cash risk within 12 months.
Liquidity ratio (2024)
?
Liquidity ratio
Definition
Ability to meet short-term debts with current assets.
Formula
Current assets / Current liabilities
Interpretation
> 1.5 : Very good 1-1.5 : Fair < 1 : Liquidity risk
158.001
Liquidity indicators evolution EURL PHARMACIE SAINT YZAN
Visualisation créée via abddaf.fr Sources : INPI & BCE - Retraitements : Ministère de l'économie
Indicator
2016
2017
2019
2020
2021
2022
2023
2024
Liquidity ratio
171.461
193.262
159.721
531.571
364.055
175.054
185.399
158.001
Interest coverage
None
None
None
None
None
None
None
None
Sector positioning
Liquidity ratio
158.02024
2022
2023
2024
Q1: 129.46
Med: 182.14
Q3: 260.79
Average
In 2024, the liquidity ratio of EURL PHARMACIE SAINT YZAN (158.00) ranks below the median of the sector. This ratio measures the ability to cover short-term debt with current assets. An improvement would strengthen the competitive position.
Positioning of EURL PHARMACIE SAINT YZAN in its sector
Comparison with sector Commerce de détail de produits pharmaceutiques en magasin spécialisé
Valuation estimate
Based on 225 transactions of similar company sales
in 2024,
the value of EURL PHARMACIE SAINT YZAN is estimated at
1 553 648 €
(range 1 081 936€ - 2 324 347€).
This multiples method compares the actual sale price of similar companies to their financial indicators (Revenue, EBITDA, Net Income). It provides a market-based indicative estimate.
Estimated enterprise value2024
225 transactions
1081k€1553k€2324k€
1 553 648 €Range: 1 081 936€ - 2 324 347€
NAF 5 année 2024
Valuation method used
Net Income Multiple
111 287 €
×
14.0x
=1 553 649 €
Range: 1 081 936€ - 2 324 347€
Only this financial indicator is available for this company.
Valuation evolution
Visualisation creee via abddaf.fr Sources : BODACC & INPI
How is this estimate calculated?
This estimate is based on the analysis of 225 actual transactions of similar company sales (same NAF code) registered with BODACC between 2016 and 2025.
EBITDA Multiple: Preferred method for profitable SMEs. EBITDA reflects the ability to generate cash.
Revenue Multiple: Used for growing companies or those with low profitability. Reflects commercial potential.
Net Income Multiple: Relevant for mature companies with stable results.
This estimate is provided for information purposes only. A precise valuation requires in-depth analysis (assets, liabilities, prospects, market...).
Similar companies (Commerce de détail de produits pharmaceutiques en magasin spécialisé)
Compare EURL PHARMACIE SAINT YZAN with other companies in the same sector:
Frequently asked questions about EURL PHARMACIE SAINT YZAN
What is the revenue of EURL PHARMACIE SAINT YZAN ?
The revenue of EURL PHARMACIE SAINT YZAN is not publicly disclosed (confidential accounts filed with INPI).
Is EURL PHARMACIE SAINT YZAN profitable?
Yes, EURL PHARMACIE SAINT YZAN generated a net profit of 111 k€ in 2024.
Where is the headquarters of EURL PHARMACIE SAINT YZAN ?
The headquarters of EURL PHARMACIE SAINT YZAN is located in SAINT-YZAN-DE-SOUDIAC (33920), in the department Gironde.
Where to find the tax return of EURL PHARMACIE SAINT YZAN ?
The tax return of EURL PHARMACIE SAINT YZAN is available on this page. Click on a year in the 'Data by year' section to view the account details (assets, liabilities, income statement). Data comes from INPI (National Institute of Industrial Property).
In which sector does EURL PHARMACIE SAINT YZAN operate?
EURL PHARMACIE SAINT YZAN operates in the sector Commerce de détail de produits pharmaceutiques en magasin spécialisé (NAF code 47.73Z). See the 'Sector positioning' section above to compare the company with its competitors.
Item evolution
Rotate your phone to landscape mode to view the chart